{"id":61737,"date":"2025-08-18T10:05:42","date_gmt":"2025-08-18T08:05:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/"},"modified":"2025-08-18T10:05:42","modified_gmt":"2025-08-18T08:05:42","slug":"anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/","title":{"rendered":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Financing supports execution of early-stage clinical trials for Anocca\u2019s lead programme VIDAR-1, powered by the Company\u2019s leading-edge R&amp;D platform, to target pancreatic cancer<\/i><\/li>\n<li>\n<i>VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open<\/i><\/li>\n<\/ul>\n<p>S\u00d6DERT\u00c4LJE, Sweden&#8211;(BUSINESS WIRE)&#8211;Anocca AB (\u2018Anocca\u2019 or the \u2018Company\u2019), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca\u2019s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca\u2019s preclinical pipeline. The financing was led by Mellby G\u00e5rd with strong support from AMF, Ramsbury and existing shareholders, alongside new investors.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/5\/Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/5\/Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/21\/Logo.jpg\"><\/a><\/p>\n<p>\nRecruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands.<\/p>\n<p>\nReagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: \u201cWe thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.\u201d<\/p>\n<p>\nJohan Andersson, Chairman of Mellby G\u00e5rd, commented: \u201cWe have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.\u201d<\/p>\n<p>\nSEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors.<\/p>\n<p class=\"bwalignc\">\n<b>ENDS<\/b><\/p>\n<p>\n<b>About Anocca<\/b><\/p>\n<p>\nAnocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments.<\/p>\n<p>\nAnocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca\u2019s TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca\u2019s facilities in S\u00f6dert\u00e4lje, Sweden. 130+ staff from 40+ nations work at Anocca.<\/p>\n<p>\n<b>About the VIDAR-1 clinical programme<\/b><\/p>\n<p>\nVIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I\/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II.<i> <\/i>Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product.<\/p>\n<p>\nMore information about the clinical trial can be found at the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Feuclinicaltrials.eu%2Fsearch-for-clinical-trials%2F%3Flang%3Den%26EUCT%3D2024-513900-32-00&amp;esheet=54308915&amp;newsitemid=20250818046061&amp;lan=en-US&amp;anchor=EU%26%238217%3Bs+clinical+trials+website&amp;index=1&amp;md5=2bd5c57225fe0a164cb39d90c656b4f1\" rel=\"nofollow\" shape=\"rect\">EU\u2019s clinical trials website<\/a>.<\/p>\n<p>\n<b>About KRAS and PDAC<\/b><\/p>\n<p>\nMutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2).<\/p>\n<p>\nReferences<\/p>\n<p>\n1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. <i>World J Oncol<\/i>. 10(1):10\u201327. doi: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.14740%2Fwjon1166&amp;esheet=54308915&amp;newsitemid=20250818046061&amp;lan=en-US&amp;anchor=10.14740%2Fwjon1166&amp;index=2&amp;md5=6d8ee1627baf7ed77affa8c6bd33c7f6\" rel=\"nofollow\" shape=\"rect\">10.14740\/wjon1166<\/a><\/p>\n<p>\n2.<b> <\/b>Hu &amp; O\u2019Reilly (2023). Therapeutic developments in pancreatic cancer. <i>Nat Rev Gastroenterol Hepatol<\/i> 21, 7\u201324. doi: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1038%2Fs41575-023-00840-w&amp;esheet=54308915&amp;newsitemid=20250818046061&amp;lan=en-US&amp;anchor=10.1038%2Fs41575-023-00840-w&amp;index=3&amp;md5=919f5dc17595a4ff7afb36995d0b95d9\" rel=\"nofollow\" shape=\"rect\">10.1038\/s41575-023-00840-w<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Inquiries<\/b><br \/><b>Anocca AB<\/b><br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.anocca.com%2F&amp;esheet=54308915&amp;newsitemid=20250818046061&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.anocca.com%2F&amp;index=4&amp;md5=0555823445b55b6770ed950bded6be97\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.anocca.com\/<\/a><br \/>Zach Chia<br \/>\n<br \/>VP Strategy &amp; Business Development<br \/>\n<br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mynewsdesk.com%2Fse%2Fanocca-ab%2Flatest_media&amp;esheet=54308915&amp;newsitemid=20250818046061&amp;lan=en-US&amp;anchor=Media+kit+is+available+here&amp;index=5&amp;md5=261cf7d8c4545ee044366c684af4ea5d\" rel=\"nofollow\" shape=\"rect\">Media kit is available here<\/a><\/p>\n<p>\n<b>FTI Consulting (For Anocca AB)<\/b><br \/>Michael Trace \/ Tim Stamper<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#97;&#110;&#111;cca&#64;&#x66;&#x74;&#x69;&#x63;&#x6f;&#x6e;&#115;&#117;&#108;&#116;&#105;ng&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">anoc&#99;&#97;&#64;&#102;&#116;&#x69;&#x63;&#x6f;&#x6e;&#x73;&#x75;&#x6c;ting&#46;&#99;&#111;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Financing supports execution of early-stage clinical trials for Anocca\u2019s lead programme VIDAR-1, powered by the Company\u2019s leading-edge R&amp;D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open S\u00d6DERT\u00c4LJE, Sweden&#8211;(BUSINESS WIRE)&#8211;Anocca AB (\u2018Anocca\u2019 or the \u2018Company\u2019), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61737","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Financing supports execution of early-stage clinical trials for Anocca\u2019s lead programme VIDAR-1, powered by the Company\u2019s leading-edge R&amp;D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open S\u00d6DERT\u00c4LJE, Sweden&#8211;(BUSINESS WIRE)&#8211;Anocca AB (\u2018Anocca\u2019 or the \u2018Company\u2019), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T08:05:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer\",\"datePublished\":\"2025-08-18T08:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/\"},\"wordCount\":672,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818046061\\\/en\\\/2554445\\\/22\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/\",\"name\":\"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818046061\\\/en\\\/2554445\\\/22\\\/Logo.jpg\",\"datePublished\":\"2025-08-18T08:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818046061\\\/en\\\/2554445\\\/22\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250818046061\\\/en\\\/2554445\\\/22\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend","og_description":"Financing supports execution of early-stage clinical trials for Anocca\u2019s lead programme VIDAR-1, powered by the Company\u2019s leading-edge R&amp;D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy in Europe with recruitment open S\u00d6DERT\u00c4LJE, Sweden&#8211;(BUSINESS WIRE)&#8211;Anocca AB (\u2018Anocca\u2019 or the \u2018Company\u2019), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-18T08:05:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer","datePublished":"2025-08-18T08:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/"},"wordCount":672,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/","url":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/","name":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg","datePublished":"2025-08-18T08:05:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250818046061\/en\/2554445\/22\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61737"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61737\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}